Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level
NCT ID: NCT07170735
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
85 participants
OBSERVATIONAL
2026-01-01
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The standard duration of TB treatment is 6 months, with a longer duration up to 12 months required for certain types of EPTB or in patients with underlying comorbidities (e.g. diabetes mellitus). Treatment monitoring and surveillance for relapses are typically based on a composite of clinical symptoms, sputum MTB culture status, and radiographical appearance. All these domains have their drawbacks, including subjective reporting (clinical symptoms), long turnaround times (sputum MTB culture status), and a lack of diagnostic sensitivity (changes in radiographical appearance in PTB). These clinical unmet needs may be overcome if a non-invasive molecular test could accurately quantify the burden of MTB in the body. Recently, it was reported that the level of MTB cfDNA in plasma can be measured by the CRISPR-TB assay. However, the data were derived mainly from the paediatric patient group and did not evaluate the possibility of latent TB infection (LTBI). This new technology remains explorative at the moment.
Our group has developed a metagenomic sequencing-based assay for measuring the level of MTB cell-free DNA (cfDNA) in plasma. We hypothesize that this new plasma MTB cfDNA assay has the potential to diagnose active TB disease, treatment monitoring and surveillance monitoring by serially measuring the MTB cfDNA level in the plasma. Similar technology may also be applicable to urine, which requires prospective validation.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TB group
patients with active TB disease
Plasma MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the plasma
Urine MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the urine
LTBI group
patients with latent TB infection
Plasma MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the plasma
Urine MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the urine
control group
subjects without active TB disease or latent TB infection
Plasma MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the plasma
Urine MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the urine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the plasma
Urine MTB cfDNA assay
Quantitative measurement of MTB cfDNA level in the urine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LTBI group: patients without TB disease, but with LTBI diagnosed by either tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) blood test.
* Control group: patients or healthy volunteers without TB disease and LTBI
Exclusion Criteria
* Concomitant use of at least two first-line anti-TB drugs for at least 2 weeks in the past 3 months.
* Aged 17 years or younger
* Life expectancy of less than 12 months
* Failed to obtain informed consent due to the patient's refusal or cognitive impairment
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ka Pang Chan
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prince of Wales Hospital
Hong Kong, Hong Kong, Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ka Pang Chan, MBChB
Role: primary
Karen Yiu
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIQUID-MTB
Identifier Type: -
Identifier Source: org_study_id